## **ForPatients**

by Roche

## Duchenne Muscular Dystrophy (DMD)

## A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD)

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

 Trial Status
 Trial Runs In
 Trial Identifier

 Completed
 1 Countries
 NCT03375164 IRB17-00512, 2021-000077-83 SRP-9001-101

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

## Trial Summary:

This study was an open-label single-dose gene transfer therapy study evaluating the safety of delandistrogene moxeparvovec intravenous (IV) administration in boys with DMD. This study was originally designed to consist of 12 patients across 2 Cohorts. Cohort A would have included participants ages 3 months to 3 years, and Cohort B included participants ages 4 to 7 years old. No participants were enrolled in Cohort A.

Sarepta Therapeutics, Inc.  Sponsor  Phase 1 Phase		hase 2	
NCT03375164 IRB17-005 Trial Identifiers	512, 2021-000077-83 SRP-9001-101		
Eligibility Criteria	•		
Gender Male	Age >=3 Months & <= 7 Years	Healthy Volunteers	